A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Eli Lilly and Company

Summary

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition. Participation in the study will last about 58 weeks.

Eligibility

Age range: 18–75 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Meet inclusion criteria under Master Protocol CWMM (NCT06143956) Exclusion Criteria: In addition to exclusion criteria under Master Protocol CWMM (NCT06143956) * Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes * Have a laboratory value suggestive of diabetes * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure…

Locations (46)

The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona
Headlands Research - Scottsdale
Scottsdale, Arizona
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona
NorCal Medical Research, Inc
Greenbrae, California
Velocity Clinical Research, Huntington Park
Huntington Park, California
Peninsula Research Associates
Rolling Hills Estates, California

Summary

Eligibility

Interventions

Locations (46)